Inventiva Announces Abstract From LEGEND, Phase 2 Trial, Evaluating Lanifibranor In Combination With Empagliflozin In Mash At The Aasld The Liver Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Inventiva has announced an abstract from its LEGEND Phase 2 trial, which evaluates the combination of Lanifibranor and Empagliflozin in treating NASH. This will be presented at the AASLD Liver Meeting 2024.
October 21, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva's announcement of the LEGEND Phase 2 trial results for Lanifibranor in combination with Empagliflozin in NASH is significant. The presentation at AASLD 2024 could influence investor sentiment positively.
The announcement of trial results and their presentation at a major conference like AASLD can boost investor confidence and interest in Inventiva, potentially leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90